Trade

Balaxi Pharmaceuticals share price

  • NaN%Low risk
  • NaN%Moderate risk
  • NaN%Balanced risk
  • NaN%High risk
  • NaN%Extreme risk
  • 29.10(2.03%)
    May 8, 2026 15:28:12 PM IST
    • NSE
    • BSE
  • Vol : 97.13 K (NSE + BSE)
    Last 20 day avg : 76.58 K

Balaxi Pharmaceuticals is trading 2.03% upper at Rs 29.10 as compared to its last closing price. Balaxi Pharmaceuticals has been trading in the price range of 29.30 & 28.70. Balaxi Pharmaceuticals has given 6.14% in this year & 6.90% in the last 5 days. Balaxi Pharmaceuticals has TTM P/E ratio 15.70 as compared to the sector P/E of 31.41.The company posted a net profit of 0.31 Crores in its last quarter.Listed peers of Balaxi Pharmaceuticals include Aurobindo Pharma (0.67%), Pfizer (1.06%), Neuland Laboratories (2.65%).The Mutual Fund holding in Balaxi Pharmaceuticals was at -% in . The MF holding has - from the last quarter. The FII holding in Balaxi Pharmaceuticals was at 1.74% in 31 Dec 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on May 08, 2026, 12:32 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.60
    High volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.23
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -0.73
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
28.70
Highest
29.30
52 week range
Lowest
15.20
Highest
63.90
Balaxi Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Aurobindo Pharma
Bullish
1,488.500.6786,303.4722.752.430.295.52
Pfizer
Moderately Bearish
4,800.001.0621,939.0535.105.310.721.60
Neuland Laboratories
Bullish
17,759.002.6522,784.6093.6712.790.087.17
Unichem Laboratories
Moderately Bullish
384.55-1.892,694.7317.850.99-3.51
Jagsonpal Pharmaceuticals
Bullish
216.501.481,455.9531.405.131.353.18
Balaxi Pharmaceuticals Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-01-28Quarterly Results & Others
2025-11-11Quarterly Results & Others
2025-08-05Quarterly Results & Others
2025-05-30Audited Results & Others
2025-02-10Quarterly Results & Others
About the company Balaxi Pharmaceuticals
  • IndustryMajor Drugs
  • ISININE618N01022
  • BSE Code
  • NSE CodeBALAXI
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across the Americas, Africa and the Caribbean islands. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It is engaged in International Wholesale Distribution of Pharmaceuticals. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents, and Laxative. Its Boadent brand includes anticavity dental toothpaste. Its subsidiaries are Balaxi Global DMCC, Dubai and Balaxi healthcare Ecuador.
  • Management Info
  • Ashish MaheshwariExecutive Chairman of the Board, Managing Director
  • Amol MantriChief Financial Officer
  • Pranav MaheshwariSenior Vice President - Business Development
  • Mohith KhandelwalCompliance Officer, Company Secretary
  • Jignesh ShahFinance Controller, Angola
  • Ram ChawlaCountry Head, Angola
  • Bharat JawaraniSales Head, Dominican Republic
  • Manish JumnaniSales Head, Guatemala
  • Karan KapoorHead - Operations, Dominican Republic
  • Paridhi MaheshwariHead - Alternate Channels
Balaxi Pharmaceuticals Share Price FAQs

Balaxi Pharmaceuticals is trading at 29.10 as on Fri May 08 2026 09:58:12. This is 2.03% upper as compared to its previous closing price of 28.52.

The market capitalization of Balaxi Pharmaceuticals is 160.65 Cr as on Fri May 08 2026 09:58:12.

The 52 wk high for Balaxi Pharmaceuticals is 63.90 whereas the 52 wk low is 15.20

Balaxi Pharmaceuticals can be analyzed on the following key metrics -

  • TTM P/E: 15.70
  • Sector P/E: 31.41
  • Dividend Yield: 0.00%
  • D/E ratio: -

Balaxi Pharmaceuticals reported a net profit of 25.07 Cr in 2025.